Affimed reports Q2 EPS (EUR1.01) vs. (EUR1.97) last year

Reports Q2 revenue EUR0.2M vs. EU2R1.4M last year. “We continue to generate compelling data across our clinical programs,” said CEO Andreas Harstrick. “In solid tumors, our combination study is making significant progress, and we are excited to see objective responses and meaningful tumor control, even in patients with EGFR mutant lung cancer – a disease often resistant to immunomodulation. It’s particularly encouraging that these outcomes are achieved without chemotherapy, which is important given the intolerance many pretreated patients have for such treatments. Our programs in hematologic malignancies are also advancing well. Recent updates from the 12 patients of the LuminICE-203 study reveal remarkable efficacy, in an advanced Hodgkin lymphoma population that had exhausted all approved treatment options. Additionally, AFM28 continues to show promise as a monotherapy in AML. The data shared today underscore our strategy of leveraging the innate immune system in our fight against cancer and reinforce our commitment to advancing these clinical programs.”